Total revenues of $36.6 million include product and service revenues, which are expected to be about $33.6 million and would be a 42 percent increase year over year.
The company also said that preliminary full-year 2019 revenues are expected to be up 6 percent, with sample-to-answer revenues up more than 20 percent.
Insight's portfolio includes a gene expression-based immuno-oncology assay for therapy response prediction.
Of the 39 deals included in the analysis, only three exceeded $100 million in value, with the rest having significantly smaller price tags or prices that were not disclosed.
The group wants the agency to allow labs to discuss gene-drug relationships with "adequate evidence" in test reports and hold a public meeting.
The companies said the commercial partnership will help increase access to genomic information in the community oncology setting.
The oncology division of Human Longevity performs next-generation sequencing services for pharmaceutical customers and generated $10 million in revenue in 2019.
The firm said it will use the funds to advance development of its HostDx immune response gene expression tests for acute infections and sepsis.
Quidel said that it expects fourth quarter 2019 revenues to be in the range of $151 million to $152 million, which would eclipse analyst expectations.
The firm also announced an exclusive distribution deal covering Israel for its T2 Resistance, T2Bacteria, and T2Candida panels